The FDA and safe use of long-acting beta-agonists in the treatment of asthma.
Chowdhury
Badrul A
BA
Division of Pulmonary and Allergy Products, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
Dal Pan
Gerald
G
D000280:Administration, Inhalation; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000318:Adrenergic beta-Agonists / Q000009:adverse effects* / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy* / Q000401:mortality; D001993:Bronchodilator Agents / Q000627:therapeutic use; D000075202:Contraindications; D003692:Delayed-Action Preparations; D017277:Drug Approval; D004348:Drug Labeling / Q000331:legislation & jurisprudence; D004359:Drug Therapy, Combination; D006801:Humans; D014481:United States; D014486:United States Food and Drug Administration
D000305:Adrenal Cortex Hormones; D000318:Adrenergic beta-Agonists; D001993:Bronchodilator Agents; D003692:Delayed-Action Preparations